Nido Biosciences
Nido Bio: Developing precision medicines for severe neurological diseases using advanced neuroscience.
Founded
2018Nido Bio: Developing precision medicines for severe neurological diseases using advanced neuroscience.
Nido Biosciences is a clinical-stage company founded with the mission to develop precision medicines for severe neurological diseases. Utilizing the latest advances in neuroscience and human genetics, Nido Bio aims to create treatments that address the fundamental biology of these conditions and restore healthy cell function. Their market focus is on severe neurological illnesses, leveraging cutting-edge scientific research to push the boundaries of what is possible in drug discovery and development.
The company is supported by a team of dedicated drug development and neuroscience experts, along with world-class scientific advisors and leading industry investors. Nido Biosciences has achieved significant milestones in translating neuroscience breakthroughs into potential treatments, making a notable impact in the field of precision medicine for neurological diseases. Their innovative approach has positioned them as a key player in the biopharmaceutical industry, driving forward the development of targeted therapies for complex neurological conditions.
Companies similar to Nido Biosciences include Neuron23, Rapport Therapeutics, Neurogene and Praxis Precision Medicines.
Nido Biosciences was founded in 2018.
Nido Biosciences' headquarters is located in Boston, MA, US.
Nido Biosciences' most recent funding round was for $86.6M (USD) in May 2023.
As of May 15, 2023, Nido Biosciences has disclosed funding of $109M (USD). Undisclosed round amounts are excluded.
Nido Biosciences has 30 employees as of Feb 5, 2024.
Praxis Precision Medicines
